Lexeo Therapeutics

June marks Alzheimer’s & Brain Awareness Month. Did you know that the risk of developing Alzheimer’s disease may be influenced by your genes? People who are APOE4 homozygous, meaning they have two copies of a gene variant called APOE4, are approximately 15 times more likely to develop Alzheimer’s.     Lexeo is developing CNS-focused gene therapies to address the underlying genetic cause of APOE4-associated Alzheimer’s disease.    Learn more about our programs here:  https://lnkd.in/g2BGvuSM     #ENDALZ #ALZScience 

Our leadership team truly valued the opportunity to connect professionally and personally during a recent offsite.    We focused on how we can potentially bring #genetherapy candidates to patients more quickly and discussed how Lexeo values can bolster our day-to-day culture and organizational goals.    We also had time for some fun! Check out some of our photos! #OneLexeo

As we close out #FAAwarenessMonth, we want to take a moment and commemorate the incredible network of individuals, families, researchers and advocates in the Friedreich ataxia (FA) community.      Last week, we were fortunate to host Jen Farmer, CEO of the Friedreich's Ataxia Research Alliance (FARA), along with members of the FA community, at our New York office. Colleagues learned more about the important work FARA is doing in FA and heard important perspectives from a patient and caregivers about their journeys. It was inspiring to hear from the FA community directly, and it reinforced our commitment to the patient community. #FriedreichAtaxia #RareDisease #OneLexeo

We are delighted to welcome José Manuel (Manny) Otero as the new Chief Technical Officer (CTO) of Lexeo. With a wealth of experience in bioprocess development, manufacturing, and clinical-stage therapeutics, Manny will lead our CMC and technical operations team as we work to advance #genetherapy research.   Join us in welcoming Manny to #Lexeo!

Today on Friedreich Ataxia Awareness Day, we honor the individuals, caregivers, families and friends who are impacted by FA. The toll FA exacts on individuals and their loved ones is profound, yet the resilience of the FA community is remarkable.  To learn more about the individuals who make the FA community so special, visit Friedreich's Ataxia Research Alliance (FARA)’s "Meet the Community" page: https://lnkd.in/eRytpGwW   #FAAwarenessMonth #FAAwarenessDay #CureFA 

Did you know that an estimated 60% of people affected by Friedreich ataxia (FA) will develop FA-related cardiomyopathy?    As FA progresses, patients typically experience various heart conditions, including thickening of the heart and arrhythmias. Cardiac complications are the leading cause of death from FA. There are currently no approved treatments for FA cardiomyopathy.   Lexeo is aiming to address this unmet need with LX2006, an AAV-based gene therapy candidate designed to treat FA cardiomyopathy. Learn more about our approach here:https://lnkd.in/exYWF9U7   #FAAwarenessMonth #CureFA

A recent story in The New York Times reporting on a publication from Springer Nature Group offers a new perspective on the genetic underpinnings of Alzheimer's disease. The publication reports that people with two copies of the APOE4 gene variant (homozygous) have a vastly increased risk of developing Alzheimer's disease. It also reinforces the critical role of genetics in understanding and treating Alzheimer’s, paving the way for innovative approaches like gene therapy. At Lexeo, our gene therapy candidate, LX1001, is being investigated in APOE4 homozygous patients with Alzheimer’s disease, which we hope may one day help people with this genetic mutation. Read the NYT article here:      https://lnkd.in/eE3mkmfm

Today, we are pleased to share our first quarter 2024 financial results and operational highlights. Visit our ‘News & Events’ page to learn more about our latest progress. https://lnkd.in/ervrfqqZ

Join us tomorrow as our SVP Clinical Development and Translational Science, Cardiology, Dr. Jordan Shin presents at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Baltimore about clinical dose-selection of AAV therapies. Find the program details here: https://lnkd.in/dHgkVjV

Every year, leaders in genetic medicine gather at American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. This year is no different! Our partners at Weill Cornell Medicine are presenting Lexeo-supported research covering advancements in gene therapy targeting Alzheimer's and genetic cardiac diseases. #ASGCT2024